Fludara Related Published Studies
Well-designed clinical trials related to Fludara (Fludarabine)
Clofarabine +/- fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. [2011.06]
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. [2011.04.01]
A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. [2011.03]
Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). [2010.04.10]
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. [2010.04.01]
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. [2009.11.01]
Fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia: no country for old men? [2009.03]
Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study. [2009.02]
Fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia: no country for old men? [2009.01.20]
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. [2007.03.20]
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. [2007.03.01]
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). [2006.12.15]
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. [2006.09.01]
Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. [2006.06.15]
Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma. [2006.04.01]
Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia. [2005.12.01]
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. [2005.10]
The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma. [2005.06]
Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders. [2005.03]
Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies. [2005.03]
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. [2004.11.15]
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. [2004.07.01]
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. [2004.04.15]
Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study. [2003.12]
Lymphocyte depletion with fludarabine in patients with psoriatic arthritis: clinical and immunological effects. [2003.11]
Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomised phase II-study. [2003.06]
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). [2003.01.01]
Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen. [2002.12.15]
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. [2002.12.15]
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. [2002.07]
Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone. [2002.02]
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. [2001.12.15]
Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease. [2001.11.01]
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. [2001.10.15]
Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. [2001.08.15]
Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis. [2001.05]
The bioavailability of oral fludarabine phosphate is unaffected by food. [2001]
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. [2000.12.14]
Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. [2000.12]
Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study. [2000.02]
Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. [2000.02]
Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte. [1999.10]
Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. [1999.05]
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. [1999.04.15]
Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. [1998.06]
Results of a fludarabine induction and alpha-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. [1997.08]
Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. [1996.05.25]
Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. [1994.01]
Absence of minimal residual disease detectable by FACS, Southern blot or PCR in patients with chronic lymphocytic leukaemia treated with fludarabine. [1994]
Well-designed clinical trials possibly related to Fludara (Fludarabine)
The effect of zinc sulfate in the prevention of high-dose chemotherapy-induced
mucositis: a double-blind, randomized, placebo-controlled study. [2012]
Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. [2011.07]
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. [2011.06.16]
Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. [2011.06.09]
Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. [2011.06.01]
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. [2011.02.01]
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. [2010.12.11]
TP53 mutation and survival in chronic lymphocytic leukemia. [2010.10.10]
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. [2007.03.01]
Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. [2006.08]
Chlorambucil plus theophylline vs chlorambucil alone as a front line therapy for B-cell chronic lymphatic leukemia. [2004.10]
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). [2004.06]
[Modified FLAG regimen in the management of refractory acute myeloid leukemia] [2003.10]
Rituximab plus chemotherapy in follicular and mantle cell lymphomas. [2003.02]
Saquinavir: a review of its use in boosted regimens for treating HIV infection. [2003]
[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group] [2002.10.25]
Evaluating treatment strategies in advanced Waldenstrom macroglobulinemia: use of quality-adjusted survival analysis. [2001.09]
Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia. [2001.08]
Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis. [2001.07]
A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials. [1994.12]
Objective antitumor activity of acivicin in patients with recurrent CNS malignancies: a Southwest Oncology Group trial. [1991.08]
Other research related to Fludara (Fludarabine)
Substitution of cyclophosphamide in the modified BuCy regimen with fludarabine is
associated with increased incidence of severe pneumonia: a prospective,
randomized study. [2013]
CYP2B6*6 is an independent determinant of inferior response to fludarabine plus
cyclophosphamide in chronic lymphocytic leukemia. [2013]
A randomized phase II trial of fludarabine/melphalan 100 versus
fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell
transplantation for patients with multiple myeloma. [2013]
A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide
plus fludarabine for allogeneic hematopoietic cell transplantation in patients
with aplastic anemia and hypoplastic myelodysplastic syndrome. [2012]
Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic
leukemia. [2012]
Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for
the treatment of previously untreated chronic lymphocytic leukemia. [2012]
Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. [2011.12]
Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. [2011.12]
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. [2011.11.10]
Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis. [2011.10]
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. [2011.09.29]
A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. [2011.09.16]
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. [2011.09.01]
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. [2011.08.25]
Fludarabine versus chlorambucil: is the debate over? [2011.06]
High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. [2011.01]
Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. [2011]
Fludarabine versus chlorambucil: is the debate over? [2011]
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic
lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine:
long-term follow-up of US Intergroup Study E2997. [2011]
Chemoimmunotherapy with fludarabine and rituximab produces extended overall
survival and progression-free survival in chronic lymphocytic leukemia: long-term
follow-up of CALGB study 9712. [2011]
U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia. [2011]
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. [2010.10.02]
Fludarabine based conditioning chemotherapy For Allogeneic Hematopoietic Stem Cell Transplantation in acquired Severe Aplastic Anemia. [2010.08.21]
[Successful treatment of B-cell prolymphocytic leukemia (B-PLL) with FCR-Lite (fludarabine, cyclophosphamide, rituximab) protocol] [2010.08.01]
Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options. [2010.07]
Successful engraftment with fludarabine, cyclophosphamide and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multi-center study. [2010.05.25]
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. [2009.10.15]
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. [2009.10]
Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma. [2009.10]
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. [2009.09.24]
Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. [2009.09.20]
|
